Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking forward to seeing the results...$RMTI
“This is an important step for Rockwell Medical and home infusion patients as we believe that FPC is uniquely suited to address this important unmet clinical need,” said Russell Ellison, M.D., President and Chief Executive Officer of Rockwell Medical. “We expect to finalize our Phase 2 clinical study design and protocol with the advice and guidance of the FDA.”
ROCKWELL MEDICAL, INC. FILES PRE-IND MEETING REQUEST WITH FDA FOR ITS PROPOSED CLINICAL TRIAL OF FPC AS A TREATMENT FOR IRON DEFICIENCY ANEMIA IN PATIENTS RECEIVING HOME INFUSION
WIXOM, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has submitted a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (FDA) in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.
Home infusion represents a large and rapidly growing segment of healthcare. Many patient groups requiring home infusion therapies suffer from chronic diseases that are associated with a high incidence of iron deficiency and anemia. For example, it is estimated that 40%-55% of all home parenteral nutrition patients are iron deficient. Current treatment patterns can be inadequate for patients on home infusion therapy with iron deficiency anemia, causing them to suffer extreme fatigue and can result in serious health risks, such as, poor immune function and heart failure.
“This is an important step for Rockwell Medical and home infusion patients as we believe that FPC is uniquely suited to address this important unmet clinical need,” said Russell Ellison, M.D., President and Chief Executive Officer of Rockwell Medical. “We expect to finalize our Phase 2 clinical study design and protocol with the advice and guidance of the FDA.”
About Rockwell Medical
Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. The Company is developing FPC for the treatment of iron deficiency in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting, a large and rapidly growing segment of healthcare, and where these patients suffer from chronic diseases associated with high incidence of iron deficiency and anemia. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit http://www.RockwellMed.com .
Rockwell Medical Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as, “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “can,” “would,” “develop,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates, expectations and beliefs and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical’s SEC filings), that could cause actual results to differ materially from those described in the forward-looking statements. Actual results could be materially different. Risks and uncertainties include, but are not limited to statements regarding the therapeutic benefits, plans and objectives for regulatory approval of the Company’s product(s); ability to obtain FDA approval and advance our product to market; risks associated with our development work, including delays, or changes to the timing, cost and success of our product development activities and clinical trials; risks of delay in the FDA approval of FPC; risks inherent in the marketing, sales and commercializing a new product; risks relating to the size and growth of the home infusion market and acceptance of FPC; risks of sufficient capital and cash resources, including access either debt or equity financing to fund such product development; and the risk of compliance with all FDA and other government requirements relating to the development and manufacturing of our product; the impact of the COVID-19 pandemic (including, applicable international or domestic orders) on our ability to operate Rockwell’s manufacturing facilities in a manner that avoids any disruptions, expected financial performance, including cash flows, revenues, growth, margins, funding, liquidity and capital resources, and those risks more fully discussed in the “Risk Factors” section of our Quarterly Report on Form 10-Q for the period ended March 31, 2021 and of our Annual Report on Form 10-K for the year ended December 31, 2020, as such descriptions may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.
ROCKWELL MEDICAL CONTACTS
Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
“This is an important step for Rockwell Medical and home infusion patients as we believe that FPC is uniquely suited to address this important unmet clinical need,” said Russell Ellison, M.D., President and Chief Executive Officer of Rockwell Medical. “We expect to finalize our Phase 2 clinical study design and protocol with the advice and guidance of the FDA.”
RMTI
* * $RMTI Video Chart 04-23-2021 * *
Link to Video - click here to watch the technical chart video
So are we ging to $5 ?
This week will take offfff
lets move up. bit of volume please
* * $RMTI Video Chart 09-23-2020 * *
Link to Video - click here to watch the technical chart video
* * $RMTI Video Chart 09-22-2020 * *
Link to Video - click here to watch the technical chart video
* * $RMTI Video Chart 09-10-2020 * *
Link to Video - click here to watch the technical chart video
Nice volume and some upward movement coming in the last two days!
Hopefully it’s the start of a bigger move.
GLTA,
Murocman
LOST ON THAT ONE... RMTI
ON TO AQST PDUFA DATES 5/21/2020 & 9/27/2020
Check out this potential, REMEMBER CLICK ON DRUG INFORMATION
https://www.biopharmcatalyst.com/company/AQST
Rockwell’s analyst coverage has been very favorable:
IFS SECURITIES – STRONG BUY
PIPER SANDLER – STRONG BUY
H C Wainwright – STRONG BUY
The potential for upside if the drug is approved this week could be massive.
I think you are right investor//// after the weekend maybe some will wake up!!!
The Rockwell Medical Inc. (NASDAQ:RMTI) team consists of winners from within the pharmaceutical sector, including a President and CEO who served as Corporate Officer and VP of Abbott Laboratories, leading its largest global business unit with $600 million of revenues.
Now it’s the potential for Rockwell Medical through Triferic to capture market potential in excess of $1 billion. This potential has not been ignored by the analysts currently covering and targeting Rockwell Medical Inc. (NASDAQ:RMTI).
Little-Known Drug Developer is on the Brink of Getting FDA Approved
The condition is… anemia.
It’s an iron deficiency disorder—often associated with diabetes mellitus or Type 2—that affects more than 2.8 million Americans1 and over 1.62 billion people worldwide5.
And with the growing prevalence of diabetes, which is projected to increase by 54% to more than 54.9 million Americans between 2015 and 2030, and increased societal costs related to the disease to increase at roughly the same rate to more than $622 billion by 20306… this new drug if approved is clearly very needed.
It’s time to take an in-depth look at a company possibly on the cusp of a major drug approval, that’s here to protect those with anemia and kidney disease.
https://microsmallcap.com/rockwell-medical-inc/RMTI-1/biotech-stock-pick/LP-G1
From the PR.......
About Triferic
Triferic is the only FDA-approved therapy in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic has a unique and differentiated mechanism of action which has the potential to benefit patients and health care economics. Triferic represents a potential innovative medical advancement in hemodialysis patient iron management– with the potential to become the future standard of care.[/The Company has two FDA-approved formulations of Triferic (1) Triferic Dialysate and (2) Triferic AVNU.
It will go up.. But right now everybody is focusing on INO and MRNA..
COULD YOU GIVE a or some reasons?
Awesome. Congrats to Rockwell. I got out at 2.75. Took my profit. Long term looks good for them. Watching closely the MRAG situation.
Rockwell Medical, Inc. Receives FDA Approval for Triferic® AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients
https://finance.yahoo.com/news/rockwell-medical-inc-receives-fda-152154174.html
Right now... NEWS OUT!!!
nice. Did they get the approval?
MRAG fires back:
NEW YORK, March 25, 2020 (GLOBE NEWSWIRE) -- Medical Resource Acquisition Group, LLC (MRAG), an investment company focused on facilitating the advancement of innovative healthcare companies, intends to ensure Rockwell Medical, Inc. (RMTI; NASDAQ) shareholders will not have their voting rights suppressed by the Rockwell Board of Directors, and intends to use all means available, including litigation, to protect the Rockwell shareholder’s right to vote for new, independent directors and improved, transparent Board governance.
On March 4, 2020, prior to a phone conference with Rockwell’s Chairman of the Board, John McLaughlin, MRAG submitted the necessary documents for their three new directors to be nominated for election at Rockwell’s next annual meeting, and after receiving confirmation from Rockwell prior to the March 8, 2020 deadline of receipt of the nomination materials, the Company waited until after the nomination deadline to note its technical objections to MRAG’s nominations and has since publicly stated that they intend not to recognize the MRAG submission. MRAG feels strongly that the current Rockwell Board of Directors (consisting of John McLaughlin, Stuart Paul, Russell Ellison, Lisa Colleran, John Cooper and Mark Ravich) are attempting to entrench and enrich themselves by trying to prevent and “suppress” RMTI shareholders' right to consider MRAG’s slate of new, independent directors at the Company’s next annual shareholder meeting.
On February 24, 2020, MRAG offered Rockwell and the Board of Directors $15 million for equity priced at the market on the condition that new MRAG-nominated directors be appointed to the Rockwell Board to replace Ben Wolin, Lisa Colleran, John Cooper and Mark Ravich . In view of Mr. Wolin’s subsequent resignation, MRAG still intends to proceed with its nominations of three new, independent directors to replace directors Colleran, Cooper and Ravich as MRAG feels the remaining directors have neglected to exercise a sound, fiscally prudent, successful strategy for Rockwell Medical and its shareholders while the RMTI share price has lost as much as 84% of its value and plunged to an all-time low recently trading at $1.12 per share
MRAG notes that the Rockwell has the worst Governance Quality Score, ranked by Institutional Shareholder Services (ISS). ISS, according to their website, empowers investors and companies and is today the world’s leading provider of corporate governance and responsible investment solutions. As of December 31, 2019, Rockwell Medical’s Governance Quality Score is 10 on a 1 – 10 rating scale. A decile score of 1 indicates lower governance risk, while a 10 indicates highest governance risk. Rockwell’s ISS pillar score for Audit is 10 and for Compensation is 10.
MRAG thinks the debt financing that was approved by the Rockwell directors is not in the best interest of Rockwell shareholders. MRAG believes Rockwell has not been transparent with shareholders regarding the details of the Company’s recent debt financing and amendments to its agreement with Baxter Healthcare by waiting to disclose the details in a future 10-Q, rather than in the 8-K reporting the financing and the amendment. The details missing from the 8-K that Rockwell filed on March 20, 2020, include covenants which are based on Triferic sales targets and the costs of amending the Baxter Agreement.
MRAG questions the business judgement of the Rockwell management and directors. MRAG feels that the decisions the Rockwell Board has made during the last several months have been unwise, have not benefited shareholders and have been driven by not putting their shareholders‘ interest first.
MRAG believes that if the directors interests were aligned with their shareholders interest they would have accepted $15 million in equity priced at the market and refreshed the Board with three new, independent directors, and they would not have consummated the recent debt financing,
completed four additional financings over 14 months including an ATM vehicle still in place,
given up on securing Triferic TDAPA reimbursement efforts as they have stated on their earnings call,
tried to launch Triferic commercially in the Medicare bundled payment,
hired a large sales force to try and sell Triferic in the Medicare bundled payment,
chosen not to commercially launch the FDA approved drug Calcitriol,
compensated themselves with salaries, bonuses and stock options for their lack of performance.
Mr. Khurram Shroff, General Partner of MRAG, stated “In my view, Rockwell’s debt financing is further evidence of the Board’s bad decision making and coupled with their disingenuous attempt to prevent shareholders the opportunity to vote for our three new directors at the annual meeting it clearly shows how badly they are trying to entrench and enrich themselves at the expense of their shareholders. We are focused on stopping the excessive spending on compensation for poor performance and results, improving governance, and bringing much-needed transparency to RMTI shareholders. Shareholders need a Board that puts a premium on practicing good governance, sound decisions, transparency, truth and prudent management of the Company funds. For the sake of all shareholders, we intend to use all options available to us, including litigation, in order to ensure that our slate of directors is considered by the shareholders at the upcoming annual shareholder meeting.”
MRAG is wholly-owned by Canadian, UAE-based businessman Khurram Shroff, who is an award- winning, global banking and finance leader. MRAG focuses on disruptive technologies in the healthcare space and is assisted by expert advisers from three continents who have global financial and strategic networks. Mr. Shroff is focused on investments in companies with innovative technologies that can bring advancement in treatment to patients worldwide. Mr. Shroff is driving an initiative to introduce vital, state-of-the-art, dialysis products and solutions globally. Mr. Shroff views his investment in Rockwell Medical as facilitating this initiative.
No Current Solicitation – 2020 Annual Meeting Not Yet Scheduled
Although we are not currently soliciting stockholders in respect of the 2020 Annual Meeting of Rockwell Medical, Inc.(“Rockwell”), this communication may nevertheless be deemed to be solicitation materials under applicable SEC regulations. Once Rockwell sets the relevant record and meeting dates, MRAG may determine to file relevant materials with the SEC, including a proxy statement on Schedule 14A. STOCKHOLDERS OF ROCKWELL ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING MRAG’S PROXY STATEMENT IF WE DECIDE TO SOLICIT IN OPPOSITION TO MANAGEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain the documents free of charge at the SEC’s web site. Such documents are not currently available.
Potential Participants in Solicitation
If we determine to solicit stockholders in respect of the 2020 Annual Meeting of Rockwell, MRAG, its members and controlling parties may be deemed to be participants in the solicitation of proxies and information about such parties will be included in any proxy statement we file regarding the 2020 Annual Meeting once Rockwell sets the relevant record and meeting dates.
Forward Looking Statements
Certain information set forth in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward looking statements). These forward-looking statements are based on current expectations, estimates, forecasts and projections. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond MRAG’s control.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause events to differ materially from any expectations or projections of future performance or result expressed or implied by such forward looking statements. These risks include, among other things: (i) market perception regarding MRAG and the viability of the proposed transactions; (ii) the availability of financing for the proposed transaction with Rockwell Medical; and (iii) the recent outbreak of the novel coronavirus and the global impact it may have on financial markets and the life sciences sector.
Although forward-looking statements contained in this presentation are based upon what management of MRAG believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. MRAG undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
CONTACT:
Tien Ma
c/o Redhill Communications
011 49 163 835 8774
Contact:
Rockwell Replies:
WIXOM, Mich., March 20, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today reiterated that Medical Resource Acquisition Group LLC (MRAG) failed to properly deliver a notice of director nominations under the Company’s Bylaws within the prescribed advance notice period.
While MRAG has continued its attempts to confuse shareholders into believing otherwise, the Company has been abundantly clear in its communications with MRAG and its advisors that MRAG’s three director nominees will not stand for election at the Company’s 2020 annual meeting of stockholders. The Company will also make copies of such correspondence available on our website, https://ir.rockwellmed.com/. The Company continues to advise shareholders to exercise caution in connection with this matter.
MRAG is not going away:
Medical Resource Acquisition Group, LLC (MRAG), an investment company focused on facilitating the advancement of innovative healthcare companies, announces that it remains focused on replacing Rockwell Medical, Inc. (RMTI; NASDAQ) Directors Lisa Colleran, John Cooper and Mark Ravich. MRAG believes Director’s Colleran, Cooper and Ravich have been largely responsible for the destruction in value of the RMTI share price, which under their guidance, or lack thereof, has lost approximately 84% of its value and plunged to an all-time low trading recently at $1.12 per share.
MRAG views the Rockwell Board’s decision to announce in a press release to shareholders that it consummated a debt financing up to $35 million, and that it was a non-dilutive financing done at the urging of shareholders, to be misleading, deceptive and not in the best interest of the shareholders of Rockwell.
Mr. Khurram Shroff, General Partner of MRAG, stated, “To bring on such a huge amount of debt, approximately 32% of the market cap at time of closing, with no current or foreseeable way to pay it down, is not in the best interest of shareholders. For that matter, it is not in the best interest of anyone other than the debt holder and the bank they paid. Furthermore, for management to tell investors in the press release that it is a non-dilutive financing while also stating that the Loan Agreement includes customary warrant coverage is blatantly misleading and deceiving. Warrants are dilutive. The Board and management also left out the important terms of the loan, such as the number of warrants issued and at what strike price, the interest rate and other covenants. We also do not understand why the public offering of common stock in February 2020, done by Cantor Fitzgerald & Co, was required or helped facilitate this Debt financing as the Company has stated. Or why Cantor Fitzgerald & Co were paid for this transaction. This Board’s lack of transparency, and outright attempt to keep shareholders in the dark, is very troubling and we plan to change that once we have our seats on the Rockwell Board.”
Mr. Shroff further stated, “The Rockwell Medical management team and Board of Directors’ failure to provide appropriate governance and truly independent directors on the Board has led to a lack of operational controls, reckless spending and excessive compensation paid to Rockwell executives and directors, resulting in five, highly dilutive financings and incredibly poor stock performance. Shareholders need a Board that puts a premium on practicing good governance, transparency, truth to shareholders and prudent management of the Company funds. Shareholders also must have directors who have purchased and own stock so that directors are aligned with the shareholders best interest, which is not the case with five of the six current Rockwell directors.”
MRAG believes Lisa Colleran, John Cooper and Mark Ravich, who are up for possible reelection at the upcoming Rockwell annual meeting, have been instrumental in overseeing the reckless Board decisions and resulting devastation in value of the RMTI share price. The three directors in MRAG’s view, have been a distraction for the Board and have gone to great lengths to pay themselves excessively while hindering the conception, adoption and execution of a sound, fiscally prudent strategy for Rockwell Medical and its shareholders.
On February 24, 2020, MRAG offered funding of $15 million, for equity priced at-the-market, to Rockwell Medical along with placing three new, highly successful directors on the Rockwell Board in a bid to restructure and reinvigorate the Company and increase its share value. Mr. Shroff believes that as Directors on the Rockwell Board, he, Markus Mueller and Arthur Reynolds will bring new opportunities and new investors into the Company and help facilitate the expansion of its business interests and investment profile worldwide.
MRAG believes Rockwell’s Board of Directors, by attempting to refuse acceptance of MRAG’s slate of Directors after Rockwell confirmed to MRAG in writing that their notice of director nominations was properly delivered under the Company’s Bylaws within the prescribed advance notice period, is trying to suppress the Company shareholders’ right to vote for the directors they feel should be elected to the Company Board. MRAG views this attempt of voter suppression by the Rockwell directors to be an effort to entrench and enrich themselves, and therefore a clear violation of their fiduciary duty to shareholders. MRAG maintains that it correctly submitted its slate of directors for the upcoming annual shareholder meeting and that this was done in accordance with the bylaws of Rockwell Medical and the state laws of Delaware and its discussions with Company representatives. MRAG intends to use all options available to it, including litigation, in order to ensure that their slate of directors is considered by the shareholders at the upcoming annual shareholder meeting.
MRAG is backed by Canadian, UAE-based businessman Khurram Shroff, who is an award- winning, global banking and finance leader. MRAG focuses on disruptive technologies in the healthcare space and is assisted by expert advisers from three continents who have global financial and strategic networks. Mr. Shroff is focused on investments in companies with innovative technologies that can bring advancement in treatment to patients worldwide. Mr. Shroff is driving an initiative to introduce vital, state-of-the-art, dialysis products and solutions globally. Mr. Shroff views his investment in Rockwell Medical as facilitating this initiative.
* * $RMTI Video Chart 03-17-2020 * *
Link to Video - click here to watch the technical chart video
No Dilution. I like the financing arrangement and it appears others like it as well.
Link to original letter sent to Rockwell by Medical Acquisitions Resources:
https://www.mragworld.com/rockwelloffer
Wow. The dip hurts on my 3.00 purchase, but I added 1000 shares in2.30 range. Let's have a great conference call today.
Looks like the suitor was a scam per Rockwell letter this morning.
Bought 2,000 shares at 3.00 going into tomorrow's earnings call.
Think the news will be good.
* * $RMTI Video Chart 02-18-2020 * *
Link to Video - click here to watch the technical chart video
Look at slide 12-13 in this presentation - the numbers are big.
Rockwell Medical (RMTI) Investor Presentation - Slideshow $RMTI https://seekingalpha.com/article/4323123
I personally like the possibility of this as a 2 to 3 bagger as the market cap is just $153 million. The co already generates revenue from 1st approved drug ($60 million) - so while in losses, they do not need to depend on someone to start the sales when approved.
Anyone have an idea or seen what yearly sale of drug would be if approved. Current pice target prior to fda decision and price target after approval
* * $RMTI Video Chart 02-11-2020 * *
Link to Video - click here to watch the technical chart video
* * $RMTI Video Chart 01-15-2020 * *
Link to Video - click here to watch the technical chart video
$RMTI Bullish
https://finance.yahoo.com/news/safe-bulkers-inc-sb-good-184758594.html
Let's also examine hedge fund activity in other stocks similar to Safe Bulkers, Inc. (NYSE:SB). We will take a look at Peoples Bancorp of North Carolina, Inc. (NASDAQ:PEBK), Rockwell Medical Inc (NASDAQ:RMTI), Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), and AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). This group of stocks' market caps resemble SB's market cap.
View table here if you experience formatting issues.
As you can see these stocks had an average of 4 hedge funds with bullish positions and the average amount invested in these stocks was $7 million. That figure was $11 million in SB's case. Rockwell Medical Inc (NASDAQ:RMTI) is the most popular stock in this table. On the other hand Peoples Bancorp of North Carolina, Inc. (NASDAQ:PEBK) is the least popular one with only 2 bullish hedge fund positions. Compared to these stocks Safe Bulkers, Inc. (NYSE:SB) is more popular among hedge funds. Our calculations showed that top 20 most popular stocks among hedge funds returned 37.4% in 2019 through the end of November and outperformed the S&P 500 ETF (SPY) by 9.9 percentage points. Unfortunately SB wasn't nearly as popular as these 20 stocks and hedge funds that were betting on SB were disappointed as the stock returned 0% during the first two months of the fourth quarter and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks among hedge funds as 70 percent of these stocks already outperformed the market in Q4.
Disclosure: None. This article was originally published at Insider Monkey.
Listened to the Conference call this morning. Have to say it was excellent. CEO Stewart Paul certainly a huge improvement over Chioni IMO. Went ahead and picked up 2,000 shares this morning.
Highlight is the 75% adoption rate of facilities that did trials with Triferic. Approx $100,000 in sales in qtr 3. Seems to be just getting started.
News: $RMTI Rockwell Medical Announces Adjournment of Annual Meeting of Shareholders
- Adjournment solely to vote on Delaware reincorporation Proposal 3(a) - - Both leading independent advisory firms have issued favorable recommendations on proposal - WIXOM, Mich., June 07, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” ...
Read the whole news https://marketwirenews.com/news-releases/rockwell-medical-announces-adjournment-of-annual-meeting-of-shareholders-8318148.html
News: $RMTI Rockwell Medical, Inc. Commences Commercial Sales of Dialysate Triferic® in the U.S.
WIXOM, Mich., May 06, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a global biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal diseas...
Read the whole news https://marketwirenews.com/news-releases/rockwell-medical-inc-commences-commercial-sales-of-dialysate-triferic-xae-in-the-u-s--8121804.html
News: $RMTI Rockwell Medical, Inc. to Discuss First Quarter 2019 Financial Results on May 9, 2019
WIXOM, Mich., May 02, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. ("Rockwell Medical" or the “Company”) (Nasdaq: RMTI) today announced that the Company will release its 2019 first quarter financial results on Thursday, May 9, 2019, after the closing of the U.S. financial m...
In case you are interested https://marketwirenews.com/news-releases/rockwell-medical-inc-to-discuss-first-quarter-2019-financial-results-on-may-9-2019-8105218.html
Followers
|
49
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
430
|
Created
|
02/28/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |